Rasio rega marang prakiraan pendapatan PacBio (PACB)
The forward P/S dynamics for Pacific Biosciences (PACB) reflect a metric value of 3.80, which warrants caution in valuation. The business is currently undergoing a phase of minimum scientific capital expenditure while awaiting sales growth for new instruments. Production relies on sterile facilities and R&D centers in the US. A unique long-read DNA sequencing ecosystem makes the equipment indispensable in medicine.
Rincian analitis perusahaan Pacific Biosciences
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data utang lan likuiditas:
Total Utang marang Modal Pacific Biosciences|PACB - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Pacific Biosciences|PACB - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku PacBio Corp|PACB - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan PacBio|Rasio cepet pacb.com
- data bathi bisnis lan rasio investasi:
PACB - Penghasilan resik perusahaan|Bathi sing dikarepake Pacific Biosciences|PACB - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Pacific Biosciences of California|PACB - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA PacBio Corp|PACB - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) PacBio|PACB - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan pacb.com|PACB - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Pacific Biosciences
- indikator volume dodolan lan pendapatan:
Analisis wiwitan perusahaan:PACB (PacBio)
For Pacific Biosciences (PACB), whose scaling model relies on high-margin consumables for sequencing systems, the forward P/S dynamics serve as an indicator of market expectations regarding revenue growth rates. This metric compares current market capitalization with projected sales volume, allowing investors to determine the asset's degree of overvaluation or identify a shift in market sentiment by comparing it with historical averages.
Analisis pesaing Pacific Biosciences
Multiplikator Forward P/S TEM (Tempus AI, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Qiagen NV (QGEN)|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Repligen Inc.|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|CRSP - Rasio kapitalisasi marang dodolan sing dikarepake|WGS (GeneDx) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Ultragenyx Pharmaceutical Inc. (RARE)|Multiplikator Forward P/S BEAM|Rasio kapitalisasi marang dodolan sing dikarepake Sarepta Corp|Multiplikator Forward P/S TWST (Twist Bioscience)|10xgenomics.com (TXG) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NTLA - Rasio rega marang prakiraan pendapatan|STOK (Stoke Therapeutics Inc) - Kapitalisasi marang prakiraan pendapatan|BLFS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Wave Pharma|MAZE (Maze Therapeutics Inc) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep sionnatx.com SION|Rasio rega marang prakiraan pendapatan Prime Medicine (PRME)|Rasio kapitalisasi marang dodolan sing dikarepake Taysha Gene Therapies Inc|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|MGTX (MeiraGTx Corp) - Rega mangsa ngarep marang pendapatan|REGENXBIO Inc. - Multiplikator Forward P/S|SLDB - Multiplikator Forward P/S|OCGN: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Benitec Biopharma Inc|DSGN (Design Pharma) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan RCKT|Multiplikator Forward P/S FDMT|lexeotx.com - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|Silence Therapeutics Inc. - Multiplikator Forward P/S|PRQR - Multiplikator Forward P/S|codexis.com (CDXS) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan SGMO (sangamo.com)|NAUT (Nautilus Biotechnology, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Metagenomi Inc.|Multiplikator Forward P/S DTIL|Multiplikator forward rega marang pendapatan generationbio.com GBIO|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Exicure Inc. (XCUR)|Celsion Corporation - Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan PHIO|MBIO: Multiplikator Forward P/S|RNAZ - Rasio kapitalisasi marang dodolan sing dikarepake|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan adnas.com (APDN)|Multiplikator forward rega marang pendapatan BLUE (bluebird bio)|IPA (immunoprecise.com) - Rega forward marang dodolan|Multiplikator Forward P/S OMGA (Omega)|Singular Genomics Corp - Rasio rega marang prakiraan pendapatan|Regulus Therapeutics - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake syros.com SYRS|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TRACON Pharmaceuticals Inc. (TCON)|Rasio rega marang prakiraan pendapatan Unity Bio
